Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISE: Etanercept PK/PD in Obese Arthritis Patients
NCT04585711Phase 1Withdrawn
- Sponsor
- Duke University
- Start
- Jul 2026
- Primary completion
- Feb 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of etanercept in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), sponsored by Duke University. Primary endpoints: Clearance at 6 weeks and Volume of distribution at 6 weeks. Planned start Jul 2026; status: withdrawn.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT04585711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04585711.